risankizumab,zasocitinib,bimekizumab,adalimumab,deucravacitinib,apremilast,secukinumab
amgen,takeda,novartis,abbvie,ucb biopharma,boehringer ingelheim,bms
['skyrizi', 'bimzelx', 'poetyk,pso-1', 'be sure', 'psoriasis', 'tak-279', 'sotyktu', 'cosentyx', 'novartis', 'bristol', 'abbvie', 'takeda', 'nimbus']
#aad2023 takeda outdoes bristol s sotyktu, but are the data phenomenal or just ok? my take via 
News Editor for Vantage covering biopharma and medtech; cat lover; banana run winner